Answers are grounded in this paper and cite their sources.
Post-inflammatory hyperpigmentation (PIH) is a common acquired pigmentation disorder that frequently affects individuals with darker skin types (Fitzpatrick III–VI). It develops following inflammation or skin injury and may persist due to increased melanocyte activity and inflammatory responses. Conventional management includes topical agents such as azelaic acid, adapalene, and cysteamine, along with regular broad-spectrum sunscreen use. Selected procedures, including low-fluence 1064-nm Nd laser, may also be beneficial when used cautiously. However, aggressive treatments can sometimes worsen pigmentation. Therefore, a combination of topical therapy and photoprotection is generally preferred. Advanced drug-delivery systems such as nanogels may further improve the localized delivery, stability, and therapeutic effectiveness of anti-hyperpigmentary agents,making them a promising approach for PIH management.
No takes yet. Share an insight, caveat, or question.
Mr. Prathamesh Patil*, Mr. Prathamesh Nimbalkar1, Ms. Dhanshri A. Kalsai2, Ms. Monika S. Jangid3, Mr. Manoj P. Jaybhaye4 (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: